Patent intelligence · US
US 12103978
Methods and materials for treating cancer
Methods and materials for treating cancer
Patent details — US 12103978
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 1, 2024
- Expiration
- Sep 26, 2044
- Applicant
- SHANGHAI MIRACOGEN INC.
- Claims
- 20
- CPC classes
- A61K, A61K2039/507, A61K39/39541, A61K45/06
Quick answer
US 12103978 (Methods and materials for treating cancer) is held by SHANGHAI MIRACOGEN INC.. Status: granted. Granted Oct 1, 2024. Expires Sep 26, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SHANGHAI MIRACOGEN INC.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K2039/507, A61K39/39541, A61K45/06, A61K47/6803, A61K47/68031
More from SHANGHAI MIRACOGEN INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 12103978?
US 12103978 (Methods and materials for treating cancer) is held by SHANGHAI MIRACOGEN INC.. Status: granted. Granted Oct 1, 2024. Expires Sep 26, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12103978?
SHANGHAI MIRACOGEN INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 12103978 expire?
Our index shows an expiration date of Sep 26, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.